Actas urologicas espanolas · 2026
Prescription of PARP inhibitors (iPARP) in metastatic castration-resistant prostate cancer: a position paper of the Spanish Association of Urology (AEU) and its Uro-Oncology Group (GUO).
СтатьяКлинические рекомендацииConsensus StatementНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
González Enguita C, Pérez Fentes D, Budía Alba A, Lorenzo Gómez M F, Gómez Rivas J, Manso Aparicio C, Fernández Aparicio T, Alvárez-Ossorio Fernández J L, en representación de la Junta Directiva AEU (Asociación Española de Urología), del GUO (Grupo de Urología Oncológica) y del Patronato Rector de la FIU (Fundación para la Investigación en Urología)
Аннотация
In recent months, restrictions have been proposed on the prescription of PARP inhibitors (iPARP) by urologists in metastatic castration-resistant prostate cancer (mCRPC). The Spanish Association of Urology (AEU), its Uro-Oncology Group (GUO), and the presidents of the Regional Urology Associations consider these limitations unjustified from clinical, organizational, legal, or professional perspectives. They unduly restrict the exercise of competencies recognized in the interdisciplinary management of prostate cancer, in line with the training, experience, and current regulations of the specialty. This document argues, from scientific, clinical, and legal standpoints, that urologists are qualified and legally authorized to prescribe and administer iPARP according to current legislation and the official training program. It also advocates a collaborative model centred on the patient's care pathway and based on mutual respect among specialties, ensuring professional autonomy, continuity of care, and equitable access to therapeutic innovation.